Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

Cell-free DNA (cfDNA) is a widely used noninvasive biomarker for diagnosis and prognosis
of multiple disease states. Emerging evidence suggests that cfDNA might not just be passive …

In kidney transplantation, the use of minimally invasive damage biomarkers that are more
sensitive and specific than plasma creatinine will be crucial to enable early, actionable …

The use of routine monitoring of donor-derived cell-free DNA (dd-cfDNA) after kidney
transplant may allow clinicians to identify subclinical allograft injury and intervene prior to …

Standard noninvasive methods for detecting renal allograft rejection and injury have poor
sensitivity and specificity. Plasma donor-derived cell-free DNA (dd-cfDNA) has been …

Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive biomarker for comprehensive
monitoring of allograft injury and rejection in kidney transplantation (KTx). dd-cfDNA …

Epigenetic mechanisms play instrumental roles in gene regulation during embryonic
development and disease progression. However, it is challenging to non-invasively monitor …